Kent C. Shih
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kent C. Shih has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
Mythili Shastry
Drug Development, Sarah Cannon Research Institute , Nashville, TN
4 shared publications- David R. Spigel
Sarah Cannon Research Institute, Nashville, TN
3 shared publications Howard A. Burris
Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN, USA
3 shared publications- John D. Hainsworth
Sarah Cannon Research Institute, Nashville, Tennessee, USA
3 shared publications Dianna Shipley
Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN
2 shared publicationsGerald Steven Falchook
Sarah Cannon Research Institute, Denver, CO
2 shared publications
Latest Publications
- Open Access
- 27 September 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (10) , 541
Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma
Pamiparib, a small-molecule poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor, demonstrates strong PARP-DNA complex trapping, antitumor activity, and blood–brain barrier penetration. This phase Ib/II dose-escalation study (NCT03150862) investigated pamiparib’s tolerability/safety and efficacy when combined with radiotherapy and/or low-dose temozolomide (TMZ) in patients with treatment-naïve (Arms A and B) and recurrent/refractory (Arm C) glioblastoma. The recommended phase II dose for Arm A was pamiparib 60 mg twice daily (BID) for 6 weeks with 6–7 weeks radiotherapy; the recommended dose for Arm C was pamiparib 60 mg BID plus 60 mg TMZ (days 1–7; 28-day cycle). The Arm B escalation cohort completed enrollment; the expansion cohort was not opened. Grade ≥3 treatment-emergent adverse events (TEAEs)/serious TEAEs were observed in 55.0%/36.7% (Arm A), 44.4%/22.2% (Arm B), and 66.0%/38.3% (Arm C) of patients. Disease control and objective response rates were 67.9% and 11.3%, respectively, for treatment-naïve patients in the dose-escalation and -expansion studies, and 40.9% and 13.6%, respectively, for recurrent/refractory patients. Median overall survival for treatment-naïve MGMT unmethylated patients was 12.8 months and 7.3 months for recurrent/refractory MGMT methylated and unmethylated patients. Pamiparib with radiotherapy and/or low-dose TMZ was tolerable for treatment-naïve or recurrent/refractory glioblastoma. Treatment-emergent cytopenia was manageable and reversible with dose reductions/interruptions. Combination regimens demonstrated antitumor activity.
- 27 September 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (10) , 541
Open AccessPhase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma
Pamiparib, a small-molecule poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor, demonstrates strong PARP-DNA complex trapping, antitumor activity, and blood–brain barrier penetration. This phase Ib/II dose-escalation study (NCT03150862) investigated pamiparib’s tolerability/safety and efficacy when combined with radiotherapy and/or low-dose temozolomide (TMZ) in patients with treatment-naïve (Arms A and B) and recurrent/refractory (Arm C) glioblastoma. The recommended phase II dose for Arm A was pamiparib 60 mg twice daily (BID) for 6 weeks with 6–7 weeks radiotherapy; the recommended dose for Arm C was pamiparib 60 mg BID plus 60 mg TMZ (days 1–7; 28-day cycle). The Arm B escalation cohort completed enrollment; the expansion cohort was not opened. Grade ≥3 treatment-emergent adverse events (TEAEs)/serious TEAEs were observed in 55.0%/36.7% (Arm A), 44.4%/22.2% (Arm B), and 66.0%/38.3% (Arm C) of patients. Disease control and objective response rates were 67.9% and 11.3%, respectively, for treatment-naïve patients in the dose-escalation and -expansion studies, and 40.9% and 13.6%, respectively, for recurrent/refractory patients. Median overall survival for treatment-naïve MGMT unmethylated patients was 12.8 months and 7.3 months for recurrent/refractory MGMT methylated and unmethylated patients. Pamiparib with radiotherapy and/or low-dose TMZ was tolerable for treatment-naïve or recurrent/refractory glioblastoma. Treatment-emergent cytopenia was manageable and reversible with dose reductions/interruptions. Combination regimens demonstrated antitumor activity.
- Open Access
- 11 December 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdae220
A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma
Background: To improve survival in patients with high-grade glioma, INC280 (capmatinib) a highly selective and potent oral inhibitor of the MET receptor with robust central nervous system (CNS) penetration, was evaluated in combination with bevacizumab (BEV). Methods: There were 2 phases, dose-escalation (3+3 design) and dose-expansion, which included patients (1) who progressed during or after first-line therapy (no prior BEV), (2) who progressed during or after second-line therapy with BEV, and (3) who had unresectable high-grade glioma (no prior BEV). Results: Sixty-four patients with high-grade glioma were treated; 18 in escalation cohorts and 46 in expansion Cohorts A (21), B (15), and C (10). The maximum-tolerated dose (MTD) was not reached and the RP2D was 400 mg capmatinib PO BID (800 mg daily). Treatment continued for a median of 14 weeks and up to ~6 years in one patient. Common treatment-related adverse events (65% ≤ Grade 2) included fatigue, peripheral edema, nausea, diarrhea, ALT increased, and constipation. Headaches and seizures occurred in 11 patients; Grade 3+ events included Grade 3 headache (1) and Grade 3 seizures (4). There were no treatment-related deaths. The 12 responders to treatment (2 CRs [1 pt in escalation and 1 pt in Cohort A] and 10 PRs [2 pts in escalation and A = 6, B = 1, and C = 1]) had a median duration of response of 9.2 months. Two patients with durable responses (CR >5 years, PR >1 year) did not harbor baseline c-MET alterations. Conclusion: Capmatinib + BEV was well-tolerated but had no clear signal of activity in c-MET non-activated high-grade glioma.
- 11 December 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdae220
Open AccessA phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma
Background: To improve survival in patients with high-grade glioma, INC280 (capmatinib) a highly selective and potent oral inhibitor of the MET receptor with robust central nervous system (CNS) penetration, was evaluated in combination with bevacizumab (BEV). Methods: There were 2 phases, dose-escalation (3+3 design) and dose-expansion, which included patients (1) who progressed during or after first-line therapy (no prior BEV), (2) who progressed during or after second-line therapy with BEV, and (3) who had unresectable high-grade glioma (no prior BEV). Results: Sixty-four patients with high-grade glioma were treated; 18 in escalation cohorts and 46 in expansion Cohorts A (21), B (15), and C (10). The maximum-tolerated dose (MTD) was not reached and the RP2D was 400 mg capmatinib PO BID (800 mg daily). Treatment continued for a median of 14 weeks and up to ~6 years in one patient. Common treatment-related adverse events (65% ≤ Grade 2) included fatigue, peripheral edema, nausea, diarrhea, ALT increased, and constipation. Headaches and seizures occurred in 11 patients; Grade 3+ events included Grade 3 headache (1) and Grade 3 seizures (4). There were no treatment-related deaths. The 12 responders to treatment (2 CRs [1 pt in escalation and 1 pt in Cohort A] and 10 PRs [2 pts in escalation and A = 6, B = 1, and C = 1]) had a median duration of response of 9.2 months. Two patients with durable responses (CR >5 years, PR >1 year) did not harbor baseline c-MET alterations. Conclusion: Capmatinib + BEV was well-tolerated but had no clear signal of activity in c-MET non-activated high-grade glioma.
- 7 August 2019
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 144 (2) , 303-311
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
Current bevacizumab-based regimens have failed to improve survival in patients with recurrent glioblastoma. To improve treatment efficacy, we evaluated bevacizumab + BKM120, an oral pan-class I PI3K inhibitor, in this patient population. A brief phase I study established the optimal BKM120 dose to administer with standard-dose bevacizumab. BKM120 60 mg PO daily + bevacizumab 10 mg/kg IV every 2 weeks in 28-day cycles was then administered to patients with relapsed/refractory glioblastoma in the phase II portion. Eighty-eight patients enrolled (phase I, 12; phase II, 76). In phase I, BKM120 80 mg PO daily produced dose limiting toxicity in 3 of 6 patients; a BKM120 dose of 60 mg PO daily was established as the maximum tolerated dose. In phase II, the median progression-free survival (PFS) was 4.0 months (95% CI 3.4, 5.4), PFS at 6 months was 36.5%, and the overall response rate was 26%. Forty-two patients (57%) experienced one or more serious treatment related toxicities. The most common CNS toxicities included mood alteration (17%) and confusion (12%); however, these were often difficult to classify as treatment- versus tumor-related. The efficacy seen in this study is similar to the efficacy previously reported with single-agent bevacizumab. This regimen was poorly tolerated, despite the low daily dose of BKM120. Further development of this combination for the treatment of glioblastoma is not recommended.
- 7 August 2019
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 144 (2) , 303-311
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
Current bevacizumab-based regimens have failed to improve survival in patients with recurrent glioblastoma. To improve treatment efficacy, we evaluated bevacizumab + BKM120, an oral pan-class I PI3K inhibitor, in this patient population. A brief phase I study established the optimal BKM120 dose to administer with standard-dose bevacizumab. BKM120 60 mg PO daily + bevacizumab 10 mg/kg IV every 2 weeks in 28-day cycles was then administered to patients with relapsed/refractory glioblastoma in the phase II portion. Eighty-eight patients enrolled (phase I, 12; phase II, 76). In phase I, BKM120 80 mg PO daily produced dose limiting toxicity in 3 of 6 patients; a BKM120 dose of 60 mg PO daily was established as the maximum tolerated dose. In phase II, the median progression-free survival (PFS) was 4.0 months (95% CI 3.4, 5.4), PFS at 6 months was 36.5%, and the overall response rate was 26%. Forty-two patients (57%) experienced one or more serious treatment related toxicities. The most common CNS toxicities included mood alteration (17%) and confusion (12%); however, these were often difficult to classify as treatment- versus tumor-related. The efficacy seen in this study is similar to the efficacy previously reported with single-agent bevacizumab. This regimen was poorly tolerated, despite the low daily dose of BKM120. Further development of this combination for the treatment of glioblastoma is not recommended.
- Top Cited PapersOpen Access
- 19 January 2018
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 7
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti–programmed death-ligand 1 (PD-L1) monoclonal antibody—showed promising efficacy and a safety profile that was generally manageable and tolerable. Here, we report the efficacy of avelumab after ≥1 year of follow-up in patients with distant mMCC that had progressed following prior chemotherapy for metastatic disease. Patients and methods Patients received avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was best overall response. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Results Patients (N = 88) were followed for a minimum of 12 months. The confirmed objective response rate was 33.0% (95% CI, 23.3%-43.8%; complete response: 11.4%). An estimated 74% of responses lasted ≥1 year, and 72.4% of responses were ongoing at data cutoff. Responses were durable, with the median DOR not yet reached (95% CI, 18.0 months-not estimable), and PFS was prolonged; 1-year PFS and OS rates were 30% (95% CI, 21%-41%) and 52% (95% CI, 41%-62%), respectively. Median OS was 12.9 months (95% CI, 7.5-not estimable). Subgroup analyses suggested a higher probability of response in patients receiving fewer prior lines of systemic therapy, with a lower baseline disease burden, and with PD-L1–positive tumors; however, durable responses occurred irrespective of baseline factors, including tumor Merkel cell polyomavirus status. Conclusions With longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed after chemotherapy. Trial registration Clinicaltrials.gov identifier: NCT02155647.
- 19 January 2018
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 7
Top Cited PapersOpen AccessUpdated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti–programmed death-ligand 1 (PD-L1) monoclonal antibody—showed promising efficacy and a safety profile that was generally manageable and tolerable. Here, we report the efficacy of avelumab after ≥1 year of follow-up in patients with distant mMCC that had progressed following prior chemotherapy for metastatic disease. Patients and methods Patients received avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was best overall response. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Results Patients (N = 88) were followed for a minimum of 12 months. The confirmed objective response rate was 33.0% (95% CI, 23.3%-43.8%; complete response: 11.4%). An estimated 74% of responses lasted ≥1 year, and 72.4% of responses were ongoing at data cutoff. Responses were durable, with the median DOR not yet reached (95% CI, 18.0 months-not estimable), and PFS was prolonged; 1-year PFS and OS rates were 30% (95% CI, 21%-41%) and 52% (95% CI, 41%-62%), respectively. Median OS was 12.9 months (95% CI, 7.5-not estimable). Subgroup analyses suggested a higher probability of response in patients receiving fewer prior lines of systemic therapy, with a lower baseline disease burden, and with PD-L1–positive tumors; however, durable responses occurred irrespective of baseline factors, including tumor Merkel cell polyomavirus status. Conclusions With longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed after chemotherapy. Trial registration Clinicaltrials.gov identifier: NCT02155647.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15040
Safety analysis of regorafenib prior to selective internal radiation therapy (SIRT) using 90Y resin microspheres for the treatment (tx) of patients (pts) with refractory metastatic colorectal cancer (mCRC) with liver metastases (mets).
E15040 Background: SIRT (or radioembolization) has been successfully used in the tx of mCRC patients with liver mets who are not surgical candidates. The addition of the multi-kinase inhibitor, regorafenib to SIRT is an attractive option as anti-tumor and maintenance tx for refractory CRC. Here we present the safety analysis of the 1st of 2 cohorts of our Phase II, open-label study comparing the safety of the combination of SIRT and regorafenib where chemotherapy occurs either before or after SIRT. Methods: mCRC pts with evidence of liver mets not treatable by surgical resection or local ablation were tx with 160 mg regorafenib QD PO on days 1-21 of a 28-day cycle followed by a 1 week (wk) washout then SIRT infusion (SIR-Spheres; Sirtex, North Sydney, Australia). Liver function was evaluated 2 wks and 4 wks after SIRT, and regorafenib was re-initiated if liver function was normal. Pts were evaluated for safety, and restaged on wk 6 and 12 following SIRT. The primary objective was to evaluate the safety of this tx schema. Results: 25 pts were enrolled from 7/15 to 8/16: median age 56 yrs, 48% male; 88% colon cancer, 12%, rectal cancer; 48% KRASmt, 4% BRAFmt. 68% of pts had prior systemic therapy for metastatic disease and 80% of pts had prior CRC surgeries. Pts received a median 11 wks regorafenib. 3 pts received regorafenib, but not SIRT due to disease progression. The median activity of SIRT delivered to the liver was 38 mCi and the median lung shunt fraction was 4%. The median tumor volume treated was 76 mL. The most common tx-related adverse events (AEs) were fatigue (60% all grades [G]; 8% G3/4), decreased appetite (32% all G; 0 G 3/4), and nausea (32%, all G; G 3/4). There were 4 tx-related serious AEs (bowel perforation, intractable abdominal pain, portal hypertension, and diarrhea) and no tx-related deaths. The overall response rate was 4%. The median PFS was 4 months and the median OS was 12 months. Conclusions: The treatment of mCRC pts with liver mets with regorafenib followed by SIRT infusion was found to be tolerable in this pt population. Further efficacy analysis of this treatment schema is merited. Clinical trial information: NCT02195011.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15040
Safety analysis of regorafenib prior to selective internal radiation therapy (SIRT) using 90Y resin microspheres for the treatment (tx) of patients (pts) with refractory metastatic colorectal cancer (mCRC) with liver metastases (mets).
E15040 Background: SIRT (or radioembolization) has been successfully used in the tx of mCRC patients with liver mets who are not surgical candidates. The addition of the multi-kinase inhibitor, regorafenib to SIRT is an attractive option as anti-tumor and maintenance tx for refractory CRC. Here we present the safety analysis of the 1st of 2 cohorts of our Phase II, open-label study comparing the safety of the combination of SIRT and regorafenib where chemotherapy occurs either before or after SIRT. Methods: mCRC pts with evidence of liver mets not treatable by surgical resection or local ablation were tx with 160 mg regorafenib QD PO on days 1-21 of a 28-day cycle followed by a 1 week (wk) washout then SIRT infusion (SIR-Spheres; Sirtex, North Sydney, Australia). Liver function was evaluated 2 wks and 4 wks after SIRT, and regorafenib was re-initiated if liver function was normal. Pts were evaluated for safety, and restaged on wk 6 and 12 following SIRT. The primary objective was to evaluate the safety of this tx schema. Results: 25 pts were enrolled from 7/15 to 8/16: median age 56 yrs, 48% male; 88% colon cancer, 12%, rectal cancer; 48% KRASmt, 4% BRAFmt. 68% of pts had prior systemic therapy for metastatic disease and 80% of pts had prior CRC surgeries. Pts received a median 11 wks regorafenib. 3 pts received regorafenib, but not SIRT due to disease progression. The median activity of SIRT delivered to the liver was 38 mCi and the median lung shunt fraction was 4%. The median tumor volume treated was 76 mL. The most common tx-related adverse events (AEs) were fatigue (60% all grades [G]; 8% G3/4), decreased appetite (32% all G; 0 G 3/4), and nausea (32%, all G; G 3/4). There were 4 tx-related serious AEs (bowel perforation, intractable abdominal pain, portal hypertension, and diarrhea) and no tx-related deaths. The overall response rate was 4%. The median PFS was 4 months and the median OS was 12 months. Conclusions: The treatment of mCRC pts with liver mets with regorafenib followed by SIRT infusion was found to be tolerable in this pt population. Further efficacy analysis of this treatment schema is merited. Clinical trial information: NCT02195011.
- 16 June 2016
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 129 (2) , 281-288
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma
Meningiomas that progress after standard therapies are challenging with limited effective chemotherapy options. This phase II trial evaluated the efficacy of everolimus plus bevacizumab in patients with recurrent, progressive meningioma after treatment with surgical resection and local radiotherapy when appropriate. Patients with recurrent meningioma (WHO grade I, II, or III) following standard treatments with surgical resection and radiotherapy received bevacizumab (10 mg/kg IV days 1 and 15) and everolimus (10 mg PO daily) each 28 day cycle. Evaluation of response occurred every 2 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints included response rate, overall survival and safety. Seventeen patients with a median age of 59 years (29–84) received study treatment. WHO grades at study entry included: I, 5 (29 %); II, 7 (41 %); III, 4 (24 %); unknown, 1 (6 %). Patients received a median of 8 cycles (1–37); all patients are off study treatment. A best response of SD was observed in 15 patients (88 %), and 6 patients had SD for >12 months. Overall median PFS was 22 months (95 % CI 4.5–26.8) and was greater for patients with WHO grade II and III compared to grade I tumors (22.0 months vs 17.5 months). Four patients discontinued treatment due to toxicity (proteinuria, 2; colitis, 1, thrombocytopenia, 1). However, other grade 3 toxicity was uncommon, and no patient had grade 4 toxicity. The combination of everolimus and bevacizumab was well-tolerated, and produced stable disease in 88 % of patients; the median duration of disease stabilization of 10 months (2–29). The median PFS from this prospective trial was similar to previous retrospective reports of bevacizumab in the treatment of recurrent meningioma.
- 16 June 2016
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 129 (2) , 281-288
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma
Meningiomas that progress after standard therapies are challenging with limited effective chemotherapy options. This phase II trial evaluated the efficacy of everolimus plus bevacizumab in patients with recurrent, progressive meningioma after treatment with surgical resection and local radiotherapy when appropriate. Patients with recurrent meningioma (WHO grade I, II, or III) following standard treatments with surgical resection and radiotherapy received bevacizumab (10 mg/kg IV days 1 and 15) and everolimus (10 mg PO daily) each 28 day cycle. Evaluation of response occurred every 2 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints included response rate, overall survival and safety. Seventeen patients with a median age of 59 years (29–84) received study treatment. WHO grades at study entry included: I, 5 (29 %); II, 7 (41 %); III, 4 (24 %); unknown, 1 (6 %). Patients received a median of 8 cycles (1–37); all patients are off study treatment. A best response of SD was observed in 15 patients (88 %), and 6 patients had SD for >12 months. Overall median PFS was 22 months (95 % CI 4.5–26.8) and was greater for patients with WHO grade II and III compared to grade I tumors (22.0 months vs 17.5 months). Four patients discontinued treatment due to toxicity (proteinuria, 2; colitis, 1, thrombocytopenia, 1). However, other grade 3 toxicity was uncommon, and no patient had grade 4 toxicity. The combination of everolimus and bevacizumab was well-tolerated, and produced stable disease in 88 % of patients; the median duration of disease stabilization of 10 months (2–29). The median PFS from this prospective trial was similar to previous retrospective reports of bevacizumab in the treatment of recurrent meningioma.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 9092
The Spruce clinical trial: Double-blind randomized phase II trial of carboplatin and pemetrexed +/- apatorsen in patients with previously untreated stage IV non-squamous non-small-cell lung cancer.
9092 Background: Hsp27 is over-expressed in many cancers and is associated with inhibition of chemotherapy-induced apoptosis. Apatorsen (A) is an antisense oligonucleotide that binds to Hsp27 mRNA and inhibits Hsp27 production; A has been shown to inhibit tumor growth and sensitize tumor cells to chemotherapy in numerous malignancies, including lung. Preclinical models demonstrate increased apoptosis with pemetrexed and platinum with A treatment. This study assessed the benefit of adding A to standard 1st line chemotherapy for patients (pts) with advanced non-squamous non-small-cell lung cancer (NS-NSCLC). The primary endpoint was progression-free survival (PFS), with overall survival to be assessed later as a secondary endpoint. Methods: 155 pts with advanced NS-NSCLC were randomized 1:1, stratified by histology and smoking status. Pts received 3 IV loading doses of 600 mg A or placebo (PL) one week (wk) prior to chemotherapy. Pts received pemetrexed 500 mg/m2, carboplatin AUC 6, and 600 mg A or PL on Day 1 every 3 wks. A or PL was also administered on days 8 and 15 of each cycle. Results: 155 pts were randomized. Demographics were similar between arms: median age 66 yr vs 67 yr; males 49% vs 49%; current/former smokers 70% vs 64% for A vs PL, respectively. Median PFS was A 6.0 months (mo) vs PL 4.9 mo; HR (2-sided 95% CI) was 0.922 (0.634, 1.340), p = 0.6687. Objective response rate: A 26% vs PL 31%. Median duration of treatment was A 15 wks vs PL 19 wks. High baseline serum Hsp27 levels ( > 9.3 ng/mL) were observed in 10% of pts. For pts with high Hsp27, median PFS was A 10.8 mo vs PL 4.8 mo. Grade 3/4 treatment-related toxicities were A thrombocytopenia (28%), neutropenia (27%), anemia (18%), leukopenia (12%), vs PL thrombocytopenia (30%), neutropenia (31%), anemia (20%), leukopenia (24%). Conclusions: A was not associated with a statistically significant improvement in PFS when added to 1st line NS-NSCLC chemotherapy. Subset data suggest that high Hsp27 expression may be a method for optimally selecting pts for tx. OS data are pending and expected later this year. Clinical trial information: NCT01829113.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 9092
The Spruce clinical trial: Double-blind randomized phase II trial of carboplatin and pemetrexed +/- apatorsen in patients with previously untreated stage IV non-squamous non-small-cell lung cancer.
9092 Background: Hsp27 is over-expressed in many cancers and is associated with inhibition of chemotherapy-induced apoptosis. Apatorsen (A) is an antisense oligonucleotide that binds to Hsp27 mRNA and inhibits Hsp27 production; A has been shown to inhibit tumor growth and sensitize tumor cells to chemotherapy in numerous malignancies, including lung. Preclinical models demonstrate increased apoptosis with pemetrexed and platinum with A treatment. This study assessed the benefit of adding A to standard 1st line chemotherapy for patients (pts) with advanced non-squamous non-small-cell lung cancer (NS-NSCLC). The primary endpoint was progression-free survival (PFS), with overall survival to be assessed later as a secondary endpoint. Methods: 155 pts with advanced NS-NSCLC were randomized 1:1, stratified by histology and smoking status. Pts received 3 IV loading doses of 600 mg A or placebo (PL) one week (wk) prior to chemotherapy. Pts received pemetrexed 500 mg/m2, carboplatin AUC 6, and 600 mg A or PL on Day 1 every 3 wks. A or PL was also administered on days 8 and 15 of each cycle. Results: 155 pts were randomized. Demographics were similar between arms: median age 66 yr vs 67 yr; males 49% vs 49%; current/former smokers 70% vs 64% for A vs PL, respectively. Median PFS was A 6.0 months (mo) vs PL 4.9 mo; HR (2-sided 95% CI) was 0.922 (0.634, 1.340), p = 0.6687. Objective response rate: A 26% vs PL 31%. Median duration of treatment was A 15 wks vs PL 19 wks. High baseline serum Hsp27 levels ( > 9.3 ng/mL) were observed in 10% of pts. For pts with high Hsp27, median PFS was A 10.8 mo vs PL 4.8 mo. Grade 3/4 treatment-related toxicities were A thrombocytopenia (28%), neutropenia (27%), anemia (18%), leukopenia (12%), vs PL thrombocytopenia (30%), neutropenia (31%), anemia (20%), leukopenia (24%). Conclusions: A was not associated with a statistically significant improvement in PFS when added to 1st line NS-NSCLC chemotherapy. Subset data suggest that high Hsp27 expression may be a method for optimally selecting pts for tx. OS data are pending and expected later this year. Clinical trial information: NCT01829113.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3082
Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer.
3082 Background: IL-10 induces activation of STAT3 in CD8 T cells leads to increased survival, proliferation and cytotoxicity of CD8 T cells. In preclinical studies, PEG-IL-10 induces CD8 mediated tumor rejection and synergizes with cytotoxic chemotherapies. Anti-tumor activity of AM0010 alone was established in the ongoing phase 1 basket trial. Objective responses were observed in pts with renal cell cancer (RCC; 4 of 15pts), uveal melanoma and cutaneous T cell lymphoma. Methods: Pts with advanced pancreatic cancer (PDAC) were treated daily with AM0010 alone (n = 24) or in combination with FOLFOX (5), capecitabine (5) or gemcitabine/nab-paclitaxel (6). Pts with colorectal cancer (n = 16) were treated with AM0010 alone. Tumor responses were monitored following irRC. Immune responses were monitored through analysis of serum cytokines, activation of blood derived T cells, immunosequencing for peripheral T cell clonality and immunohistochemistry for the infiltration of tumors by CD8 T cells. Results: In 24 PDAC pts and 16 CRC pts treated with AM0010 monotherapy (1-20 mg/kg), G3/4 TrAEs were observed in 16 pts, including anemia (5), thrombocytopenia (9), fatigue (2) rash (3) and transaminitis (1). Most TrAEs were transient, only one patient discontinued treatment due to anemia. Colitis, pneumonitis or endocrine abnormalities were not observed. In 16 pts with PDAC treated with AM0010 plus chemotherapy, TrAEs were observed in 11 pts, including thrombocytopenia (10). At 8 weeks, 8 of 17 pts with PDAC and in 4 of 15 pts with CRC on AM0010 alone had stable disease (SD). 11 of 15 PDAC pts had a reduction of CA 19-9. 4 patients (3 PDAC, 1 CRC) had prolonged PFS > 6 months. The median overall survival of PDAC was 5.1 months (n = 20), and CRC was 15.4 months (n = 13; observation > 15mo). 13 of 15 PDAC pts treated with AM0010 and chemotherapy had SD, 2 had a PR. AM0010 increased PD-1+ activated CD8 T cells and the de-novo oligoclonal expansion of T cell clones in the blood. AM0010 increased tumor infiltrating Phospho STAT3+, Granzyme+ and PD1+ CD8+ T cells in tumors. Conclusions: The preliminary clinical activity and the mechanistic data indicating enhanced immune stimulation encourages continued exploration of AM0010 in “immune resistant” cancers. Clinical trial information: NCT02009449.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3082
Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer.
3082 Background: IL-10 induces activation of STAT3 in CD8 T cells leads to increased survival, proliferation and cytotoxicity of CD8 T cells. In preclinical studies, PEG-IL-10 induces CD8 mediated tumor rejection and synergizes with cytotoxic chemotherapies. Anti-tumor activity of AM0010 alone was established in the ongoing phase 1 basket trial. Objective responses were observed in pts with renal cell cancer (RCC; 4 of 15pts), uveal melanoma and cutaneous T cell lymphoma. Methods: Pts with advanced pancreatic cancer (PDAC) were treated daily with AM0010 alone (n = 24) or in combination with FOLFOX (5), capecitabine (5) or gemcitabine/nab-paclitaxel (6). Pts with colorectal cancer (n = 16) were treated with AM0010 alone. Tumor responses were monitored following irRC. Immune responses were monitored through analysis of serum cytokines, activation of blood derived T cells, immunosequencing for peripheral T cell clonality and immunohistochemistry for the infiltration of tumors by CD8 T cells. Results: In 24 PDAC pts and 16 CRC pts treated with AM0010 monotherapy (1-20 mg/kg), G3/4 TrAEs were observed in 16 pts, including anemia (5), thrombocytopenia (9), fatigue (2) rash (3) and transaminitis (1). Most TrAEs were transient, only one patient discontinued treatment due to anemia. Colitis, pneumonitis or endocrine abnormalities were not observed. In 16 pts with PDAC treated with AM0010 plus chemotherapy, TrAEs were observed in 11 pts, including thrombocytopenia (10). At 8 weeks, 8 of 17 pts with PDAC and in 4 of 15 pts with CRC on AM0010 alone had stable disease (SD). 11 of 15 PDAC pts had a reduction of CA 19-9. 4 patients (3 PDAC, 1 CRC) had prolonged PFS > 6 months. The median overall survival of PDAC was 5.1 months (n = 20), and CRC was 15.4 months (n = 13; observation > 15mo). 13 of 15 PDAC pts treated with AM0010 and chemotherapy had SD, 2 had a PR. AM0010 increased PD-1+ activated CD8 T cells and the de-novo oligoclonal expansion of T cell clones in the blood. AM0010 increased tumor infiltrating Phospho STAT3+, Granzyme+ and PD1+ CD8+ T cells in tumors. Conclusions: The preliminary clinical activity and the mechanistic data indicating enhanced immune stimulation encourages continued exploration of AM0010 in “immune resistant” cancers. Clinical trial information: NCT02009449.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 2063
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
2063 Background: Glioblastoma (GBM) is the most common CNS tumor. Patients with recurrent GBM have few treatment options and dismal prognosis. O6-methylguanine-DNA-methyltransferase (MGMT) is correlated with resistance to front-line systemic therapy with temozolomide (TMZ) and poor patient outcomes. Dianhydrogalactitol (VAL-083) is a bi-functional alkylating agent that readily crosses the blood-brain barrier and has demonstrated activity independent of MGMT in multiple GBM cell lines and cancer stem cells in vitro. VAL-083 showed promise against CNS tumors in prior NCI-sponsored clinical trials. The goal of this clinical trial is to determine the appropriate dose for VAL-083 for advancement to Phase III trials as a new treatment for recurrent GBM. Methods: Study Population: Patients must have recurrent GBM following surgery, radiation, TMZ and bevacizumab. Phase I: Open-label, single-arm dose-escalation study (3+3 design). Patients received VAL-083 on days 1, 2, 3 of a 21-day cycle, until MTD was reached. Phase II: 14 additional patients enrolled at MTD to further assess safety and outcomes. Results: Phase I: 29 patients were enrolled across 9 dose cohorts (1.5 - 50 mg/m2/d) and 40 mg/m2/d confirmed as the MTD. Myelosuppression was mild; no drug-related serious adverse events were reported at doses ≤ 40 mg/m2/d. Dose limiting toxicity (G4 thrombocytopenia) was observed at higher doses. Platelet nadir occurred around day 20 and resolved rapidly and spontaneously. A dose-related and clinically meaningful survival improvement was observed. Pharmacokinetic analyses show dose-dependent linear systemic exposure with short 1-2h plasma terminal half-life; average Cmax 781 ng/mL at 40 mg/m2/d. Phase II: 14 patients have been enrolled at 40 mg/m2/d. To date, safety observations in the Phase II cohort are consistent with Phase I. Conclusions: VAL-083 at 40 mg/m2/d exhibits a favorable safety profile and a dose-related trend toward clinically meaningful improved survival in refractory GBM patients. We expect to present median overall survival in the Phase II expansion cohort and proposed Phase III study design. Clinical trial information: NCT01478178.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 2063
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
2063 Background: Glioblastoma (GBM) is the most common CNS tumor. Patients with recurrent GBM have few treatment options and dismal prognosis. O6-methylguanine-DNA-methyltransferase (MGMT) is correlated with resistance to front-line systemic therapy with temozolomide (TMZ) and poor patient outcomes. Dianhydrogalactitol (VAL-083) is a bi-functional alkylating agent that readily crosses the blood-brain barrier and has demonstrated activity independent of MGMT in multiple GBM cell lines and cancer stem cells in vitro. VAL-083 showed promise against CNS tumors in prior NCI-sponsored clinical trials. The goal of this clinical trial is to determine the appropriate dose for VAL-083 for advancement to Phase III trials as a new treatment for recurrent GBM. Methods: Study Population: Patients must have recurrent GBM following surgery, radiation, TMZ and bevacizumab. Phase I: Open-label, single-arm dose-escalation study (3+3 design). Patients received VAL-083 on days 1, 2, 3 of a 21-day cycle, until MTD was reached. Phase II: 14 additional patients enrolled at MTD to further assess safety and outcomes. Results: Phase I: 29 patients were enrolled across 9 dose cohorts (1.5 - 50 mg/m2/d) and 40 mg/m2/d confirmed as the MTD. Myelosuppression was mild; no drug-related serious adverse events were reported at doses ≤ 40 mg/m2/d. Dose limiting toxicity (G4 thrombocytopenia) was observed at higher doses. Platelet nadir occurred around day 20 and resolved rapidly and spontaneously. A dose-related and clinically meaningful survival improvement was observed. Pharmacokinetic analyses show dose-dependent linear systemic exposure with short 1-2h plasma terminal half-life; average Cmax 781 ng/mL at 40 mg/m2/d. Phase II: 14 patients have been enrolled at 40 mg/m2/d. To date, safety observations in the Phase II cohort are consistent with Phase I. Conclusions: VAL-083 at 40 mg/m2/d exhibits a favorable safety profile and a dose-related trend toward clinically meaningful improved survival in refractory GBM patients. We expect to present median overall survival in the Phase II expansion cohort and proposed Phase III study design. Clinical trial information: NCT01478178.